Clinical trial Recruiting at 1 site Interventional Ages 18 to 55 Women only

Outcomes of transferring embryos identified as abnormal

Official title: Transfer of Aneuploid or Mosaic Embryos Following Preimplantation Genetic Testing

Run by Stanford University · NCT04109846 · Data updated 2026-11-12

This study is testing whether transferring embryos that are found to have genetic abnormalities can lead to successful pregnancies and healthy children for patients who have no other viable embryo options.

Quick facts

Study typeInterventional
Ages18 Years to 55 Years
SexWomen only
Enrollment300 (estimated)
SponsorStanford University
Academic / other
Locations1 site (Sunnyvale, California)
StatusRecruiting
StartedApril 11, 2019
Main results expectedApril 2035
Study endsApril 1, 2039
Registry record updatedApril 24, 2026
Trial IDNCT04109846 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals with available aneuploid or mosaic embryos and no other acceptable embryos, who are willing to travel to Stanford for treatment.

Probably not a fit

Patients using international donor eggs or sperm not tested according to FDA guidelines, or those living outside the United States, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the outcomes of pregnancies resulting from the transfer of embryos that have been identified as aneuploid or mosaic through preimplantation genetic testing. It will evaluate the frequency of live births from these embryos and investigate any associated risks for complications during pregnancy and potential health or developmental issues in the children during their first five years. Participants will provide medical records and pediatric data, and the study will meticulously document genetic testing results and pregnancy outcomes. The research is conducted at Stanford University, focusing on patients with no other viable embryo options.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the safety and viability of transferring embryos deemed abnormal, potentially improving reproductive outcomes for patients.

How similar studies have gone: While there have been studies on embryo transfer outcomes, this specific focus on aneuploid and mosaic embryos is relatively novel and not extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Available aneuploid or mosaic embryos
* No other acceptable embryos available
* Willing to travel to Stanford for treatment
* English language fluency

Exclusion Criteria:

* Use of international donor eggs or sperm not tested according to FDA guidelines.
* Living outside the United States
* Embryos with Triploidy are not eligible for transfer in this protocol

Where it's running

  • Stanford Fertility and Reproductive Medicine Center
    Sunnyvale, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.